DP
BCYC

Diadema Partners’s Bicycle Therapeutics BCYC Stock Holding History

Diadema Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.21M Buy
+476,424
New +$2.72M 0.38% 56

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Diadema Partners's BCYC Position: Q1 2026 in Review

Diadema Partners opened a new position in Bicycle Therapeutics (BCYC) in Q1 2026: 476,424 shares worth $2.21M. The stake represents 0.38% of the portfolio and ranks #56 among its holdings.

98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Diadema Partners held 476,424 shares of Bicycle Therapeutics worth $2.21M as of Q1 2026.
  • Bicycle Therapeutics was a new Diadema Partners position in Q1 2026.
  • Bicycle Therapeutics made up 0.38% of Diadema Partners's portfolio in Q1 2026, its #56 holding.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.